ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OXB Oxford Biomedica Plc

201.00
3.80 (1.93%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.80 1.93% 201.00 199.20 203.50 202.50 194.20 199.00 240,015 16:35:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medicinal Chems,botanicl Pds 139.99M -45.16M -0.4676 -4.31 194.61M

Oxford Biomedica PLC Bioverativ Collaboration and Licence Agreement (9382E)

15/02/2018 7:00am

UK Regulatory


Oxford Biomedica (LSE:OXB)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Oxford Biomedica Charts.

TIDMOXB

RNS Number : 9382E

Oxford Biomedica PLC

15 February 2018

Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy

Oxford, UK- 15 February 2018: Oxford BioMedica plc (LSE:OXB) ("Oxford BioMedica" or "the Group"), a leading gene and cell therapy group, today announces that it has completed a major new collaboration & licence agreement with Bioverativ Inc. for the development and manufacturing of lentiviral vectors to treat haemophilia. The agreement includes a licence to use OXB's LentiVector Enabled technology and access to its industrial-scale manufacturing technology.

Under the terms of the agreement, Oxford BioMedica will receive a $5 million upfront payment from Bioverativ. Oxford BioMedica is also eligible to receive various milestone payments, potentially worth in excess of $100 million, and undisclosed royalties on net sales of Bioverativ's lentiviral vector haemophilia products. Bioverativ will also fund process development and scale-up activities for its lentiviral vector haemophilia products at Oxford BioMedica. The agreement also allows for the parties to put in place a clinical supply agreement for GMP manufacturing of haemophilia products at Oxford BioMedica.

Commenting on the announcement, John Dawson, Chief Executive Officer of Oxford BioMedica, said: "Today's news demonstrates the value of our LentiVector Enabled platform and our leading capabilities and reputation in the industrial scale-up for lentiviral vectors for clinical and commercial supply. Bioverativ's investment in haemophilia gene therapy underlines the potential of lentiviral vectors for use for in vivo gene therapy. This new deal, potentially worth in excess of $100m, demonstrates Oxford BioMedica's strategy of building multiple partnerships with leaders in their therapeutic categories and will support the Group's continued growth. Oxford BioMedica is recognised as a world leader in the field of development and manufacturing of lentiviral vectors and we are delighted to be supporting Bioverativ in the development of gene therapy products to treat haemophilia."

-Ends-

 
  For further information, 
   please contact: 
  Oxford BioMedica plc:                     Tel: +44 (0)1865 
   John Dawson, Chief Executive              783 000 
   Officer 
   Stuart Paynter, Chief Financial 
   Officer 
  Financial and corporate communications    Tel: +44 (0)20 3709 
   enquiries:                                5700 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew 
   Neal/Philippa Gardner/Laura 
   Thornton 
 
 
 Peel Hunt (Joint Corporate     Tel: +44 (0)20 7418 
  Brokers):                      8900 
  James Steel 
  Christopher Golden 
 WG Partners (Joint Corporate   Tel: +44 (0)20 3705 
  Brokers):                      9321 
  David Wilson 
  Claes Spang 
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Notes to editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex-vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Bioverativ, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 300 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRDDGDDIXBBGIS

(END) Dow Jones Newswires

February 15, 2018 02:00 ET (07:00 GMT)

1 Year Oxford Biomedica Chart

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

Your Recent History

Delayed Upgrade Clock